KWA 0711

Drug Profile

KWA 0711

Alternative Names: KWA-0711

Latest Information Update: 25 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kissei Pharmaceutical
  • Class Laxatives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation

Most Recent Events

  • 15 Apr 2016 Kissei Pharmaceutical completes a phase I trial in Constipation (In volunteers) in United Kingdom (NCT02434835) prior to April 2016
  • 15 Apr 2016 Kissei Pharmaceutical completes a phase II trial for Constipation in Japan (NCT02343978) prior to April 2016
  • 15 Apr 2016 Kissei Pharmaceutical completes a phase II trial in Constipation in Japan (NCT02281630) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top